Kura Oncology Profile

14.1
USD 0.3  2.08%
13.6Last Month High 14.95 
13.9Trading Day  High 14.6 

Exercise or conversion by Troy Wilson of 27985 shares of Kura Oncology subject to Rule 16b-3

Kura Oncology Inc insider trading alert for exercise of option to purchase common stock by Troy Wilson, President and CEO, on August 23, 2017. This event was filed by Kura Oncology Inc with SEC on 2017-08-23. Statement of changes in beneficial ownership - SEC Form 4. Troy Wilson is currently serves as chairman of the board and presidentident, ceo, co-founder of Kura Oncology Inc [view details]   

Kura Oncology Summary

Kura Oncology Inc (KURA) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 24 people. Kura Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 390.4 M. Kura Oncology Inc has 27.69 M outstanding shares of which 568.14 K shares are now shorted by private and institutional investors with about 12.66 trading days to cover. Kura Oncology currently holds about 53.24 M in cash with (26.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.66.
Check Kura Oncology Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Bank Of MontrealCommon Shares402.4 K6 M
Mutual Of America Capital Management LlcCommon Shares5 K75 K
View Kura Oncology Diagnostics

Selected Kura Oncology Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Kura Oncology Against Markets

Risk Adjusted
Performance Score (0 to 100)
8 
Chance of
< 4% 
Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameKura Oncology Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationCALIFORNIA, U.S.A
Business AddressKura Oncology, Inc.La Jolla, CA
ExchangeNASDAQ
CIK Number01422143.0
CUSIP50127T109
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.kuraoncology.com
Contact Number858 500 8800
CurrencyUSD - US Dollar

Recommendations

Kura Oncology Analyst Recommendations
Target PriceAdvice# of Analysts
16.5Strong Buy2Odds
Kura Oncology Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Kura Oncology Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Kura Oncology Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.39March 16, 2017
Kura Oncology Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate